Menu

SIMDAX® (i.v. levosimendan)

SIMDAX® (i.v. levosimendan) is an inodilator (calcium sensitizer and potassium channel opener) indicated for the short-term treatment of acutely decompensated severe chronic heart failure (ADHF) in situations where conventional therapy is not sufficient, and in cases where inotropic support is considered appropriate.

To find out more, click on the section About SIMDAX®. If you are a healthcare professional, you can register as a user in the section for healthcare professionals for full information on SIMDAX®.

Prescribing information

SIMDAX® is indicated for the short-term treatment of acutely decompensated severe chronic heart failure (ADHF) in situations where conventional therapy is not sufficient, and in cases where inotropic support is considered appropriate. Read more.

Register here

Our section for healthcare professionals provides additional and useful information, including several videos, on SIMDAX®. Join us and register here.


1. Nieminen MS et al. Eur Heart J Suppl. 2017;19(suppl C);C15-C21
2. Papp Z et al. Int J Cardiol. 2012;159:82–87.

Read more



Acute and Advanced Heart Failure Knowledge Center »



Levosimendan in Wikipedia »



Levosimendan in PubMed »

Prescribing information

Simdax® is indicated for the short-term treatment of acutely decompensated severe chronic heartfailure (ADHF) in situations where conventional therapy is not sufficient, and in cases where inotropic support is considered appropriate. Read more.

Register here

Our section for healthcare professionals provides additional and useful information, including several videos, on Simdax®. Join us and register here.